Jun 21 |
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
|
Jun 10 |
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
|
Jun 6 |
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
|
May 16 |
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
|
May 16 |
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
|
May 15 |
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
May 7 |
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
|
May 6 |
Sagimet Biosciences gets new finance head
|
May 6 |
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
|
Apr 26 |
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
|